IGHE and allergic bronchopulmonary aspergillosis: Omalizumab α ameliorates ABPA pathogenesis by neutralizing circulating IgE and preventing its binding to the high-affinity FcεRI receptor on mast cells and basophils, thereby suppressing IgE-mediated degranulation and Th2-driven airway inflammation.